GlassScriptPhysician profile
Jake Robert Dubin
NPI 1548993017
$7,090.84
in general payments reported to CMS, 2019-2025
23 companies · $2,745 in 2025
The $2,745 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $1,656 · 2024: $2,292 · 2025: $2,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,003.20 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $1,039.64 | 2022-2025 | Precision7, Total30, Dailies Total1 |
| Tarsus Pharmaceuticals, INC. | $977.64 | 2024-2025 | Xdemvy |
| Abbvie INC. | $671.96 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Biotissue Holdings INC. | $504.27 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $408.42 | 2022-2024 | Cequa |
| Oyster Point Pharma, INC. | $247.02 | 2023-2024 | Tyrvaya |
| Sight Sciences, INC. | $169.05 | 2022-2025 | Tearcare System |
| Johnson & Johnson Vision Care, INC. | $162.74 | 2022-2025 | |
| Harrow Eye, LLC | $147.79 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $125.98 | 2024 | Dextenza |
| Amgen INC. | $121.85 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $100.46 | 2023-2024 | Tecnis Iol, Tecnis Iol |
| Coopervision INC. | $82.18 | 2024 | Misight Contact Lens |
| Mallinckrodt Hospital Products INC. | $78.20 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $66.12 | 2023 | Tepezza |
| Dompe US, INC. | $54.17 | 2023-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $33.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.74 | 2022-2023 | |
| Glaukos Corporation | $27.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.58 | 2023 | Eylea |
| Astellas Pharma US INC | $14.86 | 2025 | Izervay |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Dubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.